Related Experiment Videos
Multidisciplinary management of resectable rectal cancer
1Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Oncology (Williston Park, N.Y.)
|November 1, 1996
Summary
Standard rectal cancer treatment involves pelvic radiation and 5-FU chemotherapy. Ongoing trials are evaluating optimal chemotherapy and comparing preoperative versus postoperative therapy to improve outcomes for rectal cancer patients.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Adjuvant therapy for resectable rectal cancer typically includes pelvic radiation and fluorouracil (5-FU)-based chemotherapy.
- Optimizing chemotherapeutic agents and administration routes is crucial for postoperative treatment.
Purpose of the Study:
- To determine ideal chemotherapeutic agents and routes of administration in the postoperative setting for rectal cancer.
- To compare the efficacy and functional outcomes of preoperative versus postoperative combined-modality therapy approaches.
Main Methods:
- Two randomized intergroup trials (INT 0114 and INT 0144) are investigating postoperative chemotherapy.
- The National Surgical Adjuvant Project for Breast and Bowel Cancers (NSABP R-03) and INT 0147 are comparing preoperative and postoperative combined-modality therapies.
Main Results:
- Ongoing trials aim to establish optimal chemotherapeutic regimens for adjuvant rectal cancer therapy.
- Comparative studies will elucidate the benefits of preoperative versus postoperative treatment strategies.
Conclusions:
- Multidisciplinary collaboration among medical, surgical, and radiation oncologists is essential for effective rectal cancer treatment.
- Further research through ongoing trials will refine therapeutic approaches for resectable rectal cancer.